Research on Blood Pressure Drug for Alzheimer’s Disease

Overview of Dementia and Alzheimer’s Disease

Researchers in the Netherlands have explored the potential use of a common blood pressure medication as a treatment for Alzheimer’s disease. Dementia encompasses a range of symptoms such as memory loss, cognitive decline, personality changes, and inappropriate behavior, with several distinct types identified. Among these, Alzheimer’s disease stands out as the leading cause of progressive, irreversible dementia in the elderly, accounting for an estimated 60 to 80 percent of all cases. This condition is characterized by significant alterations in brain tissue, particularly the presence of amyloid plaques and neurofibrillary tangles.

Understanding the Causes and Effects of Alzheimer’s Disease

The exact causes of Alzheimer’s disease remain unclear, though it is believed that a mix of genetic, lifestyle, and environmental factors contribute to its onset. Notably, previous studies have indicated that blood flow to the brain diminishes in the early stages of Alzheimer’s disease. This reduction suggests that medications aimed at enhancing cerebral blood flow could potentially slow the progression of the disease.

Study on Nilvadipine and Brain Blood Flow

In this context, the researchers assessed whether nilvadipine, a frequently prescribed blood pressure medication, could enhance brain blood flow in patients diagnosed with mild to moderate Alzheimer’s disease. Their findings were published in the journal Hypertension. The study involved a randomized assignment of 44 patients to either receive nilvadipine or a placebo daily for six months.

At both the beginning and conclusion of the study, the researchers utilized specialized magnetic resonance imaging (MRI) techniques to measure brain blood flow. The results revealed a 20% increase in blood flow to the hippocampus—a region critical for memory and learning—in patients taking nilvadipine, in contrast to no significant changes observed in the placebo group.

Implications of the Findings

These results indicate that the reduction in brain blood flow experienced by Alzheimer’s patients can be partially reversed in key areas of the brain. However, the authors caution that it remains uncertain whether this improvement translates into clinical benefits for the patients, and further research is required. The MRI study participants were part of a larger project involving 500 patients with mild to moderate Alzheimer’s disease, investigating nilvadipine’s overall clinical benefits. Although no broad benefits were observed, a subgroup of patients with mild dementia symptoms exhibited a slower decline in memory.

Dr. Jurgen Claassen, the lead author from Radboud University Medical Center in Nijmegen, Netherlands, stated, “In the future, we need to find out whether the improvement in blood flow, especially in the hippocampus, can be used as a supportive treatment to slow down the progression of Alzheimer’s disease, especially in earlier stages of the disease.”

Related Topics of Interest

– Does high blood pressure increase the risk of miscarriage?
– Can a common blood pressure drug improve ovarian cancer treatment?
– Could blood pressure treatment be harmful to older seniors?
– Is poor oral health linked to worse blood pressure control?
– Nitrate-rich Vegetables and the Lowering of Blood Pressure Myth
– Can dementia be prevented with stricter blood pressure control?

References

– de Jong DLK, de Heus RAA, Rijpma A, et al. Effects of nilvadipine on cerebral blood flow in patients with Alzheimer Disease. Hypertension 2019; doi:10.1161/HYPERTENSIONAHA.119.12892.
– American Heart Association, Press release: 17 June 2019. “Hypertension drug may hold promise for Alzheimer’s disease.” https://www.eurekalert.org/pub_releases/2019-06/aha-hdm061219.php

Image by Raman Oza from Pixabay.